Aristotle Capital Boston, LLC Supernus Pharmaceuticals, Inc. Transaction History
Aristotle Capital Boston, LLC
- $3.22 Billion
- Q1 2024
A detailed history of Aristotle Capital Boston, LLC transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Aristotle Capital Boston, LLC holds 1,139,846 shares of SUPN stock, worth $30.9 Million. This represents 1.21% of its overall portfolio holdings.
Number of Shares
1,139,846
Previous 1,159,828
1.72%
Holding current value
$30.9 Million
Previous $33.6 Million
15.83%
% of portfolio
1.21%
Previous 1.05%
Shares
22 transactions
Others Institutions Holding SUPN
# of Institutions
260Shares Held
57.3MCall Options Held
84.1KPut Options Held
61.2K-
Black Rock Inc. New York, NY10.4MShares$281 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.21MShares$168 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY3.57MShares$96.9 Million1.66% of portfolio
-
Macquarie Group LTD Australia, C32.67MShares$72.4 Million0.1% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.56MShares$69.3 Million0.02% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $1.45B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...